Trial Profile
A 12 month, randomized, open-label, multicenter, study to assess the long term safety of aliskiren 150mg alone and 300mg alone or with the optional addition of hydrochlorothiazide (12.5mg or 25mg) in patients with essential hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2011
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Adverse reactions
- 01 Dec 2011 Results published in Clinical Drug Investigation.
- 07 Nov 2011 Actual initiation date (June 2004) added as reported by ClinicalTrials.gov.
- 07 Nov 2011 Actual end date (October 2005) added as reported by ClinicalTrials.gov.